Literature DB >> 26557250

Reference values for spirometry - report from the Obstructive Lung Disease in Northern Sweden studies.

Helena Backman1, Anne Lindberg2, Anders Odén3, Linda Ekerljung4, Linnéa Hedman1, Annette Kainu5, Anssi Sovijärvi6, Bo Lundbäck7, Eva Rönmark1.   

Abstract

BACKGROUND: Abnormal lung function is commonly identified by comparing observed spirometric values to corresponding reference values. It is recommended that such reference values for spirometry are evaluated and updated frequently. The aim of this study was to estimate new reference values for Swedish adults by fitting a multivariable regression model to a healthy non-smoking general population sample from northern Sweden. Further aims were to evaluate the external validity of the obtained reference values on a contemporary sample from south-western Sweden, and to compare them to the Global Lung Function Initiative (GLI) reference values.
METHOD: Sex-specific multivariable linear regression models were fitted to the spirometric data of n=501 healthy non-smoking adults aged 22-91 years, with age and height as predictors. The models were extended to allow the scatter around the outcome variable to depend on age, and age-dependent spline functions were incorporated into the models to provide a smooth fit over the entire age range. Mean values and lower limits of normal, defined as the lower 5th percentiles, were derived. RESULT: This modelling approach resulted in unbiased estimates of the spirometric outcomes, and the obtained estimates were appropriate not only for the northern Sweden sample but also for the south-western Sweden sample. On average, the GLI reference values for forced expiratory volume in one second (FEV1) and, in particular, forced expiratory vital capacity (FVC) were lower than both the observed values and the new reference values, but higher for the FEV1/FVC ratio.
CONCLUSION: The evaluation based on the sample of healthy non-smokers from northern Sweden show that the Obstructive Lung Disease in Northern Sweden reference values are valid. Furthermore, the evaluation based on the south-western Sweden sample indicates a high external validity. The comparison with GLI brought further evidence to the consensus that, when available, appropriate local population-specific reference values may be preferred.

Entities:  

Keywords:  Z-scores; linear regression; percentiles; reference equations; reference sample; spline functions

Year:  2015        PMID: 26557250      PMCID: PMC4629723          DOI: 10.3402/ecrj.v2.26375

Source DB:  PubMed          Journal:  Eur Clin Respir J        ISSN: 2001-8525


Dynamic spirometry is an important tool for the assessment of lung function in daily clinical practice. Abnormal lung function is identified by comparing an observed value with a reference value. There are a large number of published reference values for spirometry available (1–14). The Global Lung Function Initiative (GLI), an European Respiratory Society (ERS) task force, presented new multi-ethnic reference values for spirometry in 2012 (10), which currently are endorsed by several respiratory societies such as the ERS and the American Thoracic Society (ATS) (10, 15). However, it has recently been shown that the GLI reference values may not be appropriate in all countries (16–20). It is essential that the sample from which the reference values are derived is representative for the contemporary healthy non-smoking population. The age range and other anthropometric, ethnic, environmental, and socio-economic factors must be considered, since such factors can affect lung function (21). In addition, the spirometric measurements should be performed in line with recommended guidelines (22–25). It is also important that reference values for spirometry are evaluated and updated continuously (22, 24, 25). Linear regression models have commonly been used to model lung function. In most models, the predictors are sex, age, and height, but sometimes also weight and ethnicity (1–6, 9–13). It has been shown that subjects of European ancestry (Caucasians) have larger lung volumes compared with subjects of other races/ethnicities (22, 26, 27). Height is a proxy for chest size, and women have smaller lung volumes than men. Age is a proxy for maturity, and lung volumes increase by age during childhood and adolescence followed by a plateau with a subsequent decrease, with a starting point some years post adolescence (3, 10, 23). In general, there is a high variability in the lung function development in elderly subjects and the age dependence in later stages of life is less studied (24). Recently, progress has been made in the area of modelling lung function and the Lambda-Mu-Sigma (LMS) method imbedded in the generalised additive models for location, scale and shape (GAMLSS) models (28, 29) is preferred by some authors (12, 30). This method was used to derive the GLI reference values (10, 31). Beside the mean, the GAMLSS allow for skewness and kurtosis to be modelled. It is also common to use spline functions to allow both the predicted estimates and the standard deviation (SD) to vary non-linearly as functions of an explanatory variable (9, 10, 12, 30). Previous studies have shown that not only the predicted mean but also the SD vary with age, especially when including ages from childhood to adulthood (10, 31), while a large but somewhat older study indicated constant variance for adults (32). The aim of this study was to estimate new up-to-date reference values for spirometry for adults of European ancestry by fitting a multivariable regression model to data from Caucasian healthy non-smokers sampled from the general population of northern Sweden. Further aims were to evaluate the external validity of the new reference values on contemporary data of healthy non-smokers from south-western Sweden and to compare them with the GLI reference values.

Material and method

The northern Sweden reference sample

As a part of the Obstructive Lung Disease in Northern Sweden (OLIN) studies, 1,016 randomly selected respondents from a large postal questionnaire survey in 2006 (33) were invited to clinical examinations in 2008–2009. Of them, 737 subjects (72.5%) aged 21–86 years participated in structured interviews and spirometry (34). In 2011–2013, 738 additional healthy non-smokers according to the 2006 questionnaire survey were invited to identical examinations, and 448 subjects (60.6%) aged 25–91 years participated (17). The study flow chart is illustrated in Fig. 1. Information about respiratory diseases and symptoms, other diseases, and smoking history was collected at the interview. The study was approved by the Regional Ethical Review Board at Umeå University, Sweden.
Fig. 1

Study flow chart.

Study flow chart. Healthy non-smokers were defined as having none of the following criteria: usually wheeze when breathing; sputum production most days in periods of 3 months per year; ever have had asthma; been diagnosed as having asthma, chronic bronchitis, COPD or emphysema by a physician; ever use of asthma medication regularly or when needed; ever use of medication for chronic bronchitis, COPD, or emphysema; ever had ischemic heart disease; wheeze in past 12 months with concurrent breathlessness; wheeze in past 12 months without having a cold; wheeze in the past 12 months most days per week; any other disability that could affect the lung capacity; or mMRC dyspnoea scale≥2. A further exclusion criterion was a cumulative life-long smoking history of>1 pack year. The age was calculated by one decimal point as the difference between date of birth and date of examination. Date of birth was collected from the Swedish national registry. Height was measured without shoes with an accurate stadiometer with 0.5 cm precision. Weight was measured with 0.5 kg precision with empty pockets without jacket and shoes. Caucasian ethnicity was defined as a subject of European ancestry. Two Jaeger Masterscope spirometers (JLAB version 5.21 software, CareFusion, Würzburg, Germany) were used to measure forced expiratory volume in one second (FEV1), forced expiratory vital capacity (FVC), and slow expiratory vital capacity (SVC). The procedure followed the ATS/ERS recommendations (35) but with a reproducibility criterion of≤5% instead of≤150 ml deviation from the second highest value. The same highly experienced, trained, and qualified research nurses performed the measurements throughout the study. The spirometers were calibrated every morning. The highest value for FEV1, FVC, and SVC was recorded for each subject and at least three up to a maximum of eight measurements were performed to fulfil the reproducibility criterion. The mean (median) absolute differences between the highest and the second highest values were: 38 ml (27 ml) for women and 59 ml (45 ml) for men in FEV1, and 53 ml (44 ml) for women and 69 ml (54 ml) for men in FVC. In total, 2.8% of the FEV1 measurements and 6.1% of the FVC measurements deviated>150 ml. Vital capacity (VC) was defined as the highest value of FVC and SVC. In total, 501 subjects, 49% women, were identified as healthy non-smoking subjects of European ancestry with adequate spirometry quality. Further details regarding the measurements of lung function can be found in the Appendix.

Derivation of the OLIN reference values based on the northern Sweden reference sample

Normal Q–Q plots were used to evaluate and confirm normal distribution of the spirometric indices FEV1, FVC, SVC, VC, the FEV1/FVC ratio and the FEV1/VC ratio, and linear regression was used to model each outcome measure. Sex-specific multivariable linear regression models were estimated for each of the spirometric indices, with age and height as independent variables. The relationships with weight were also investigated, but as model improvements were absent or negligible, weight was omitted to keep the models parsimonious. Age-dependent spline functions were incorporated in each model to allow the outcome variable to vary smoothly over the age range. A common assumption of multivariable linear regression is that the SD around the regression function is constant (homogeneous variance). This assumption was extended to include the case when the SD is a linear function of one of the regression variables (an explanatory variable), in this case age. Further details of the statistical modelling are described in the Appendix.

Model accuracy check

Z-scores (standardised residuals) and percentiles were calculated for each subject. If the observed value has a perfect normal distribution with mean and SD equal to the mean and SD of the reference values, then mean and SD of the percentile point will be 0.50 and 0.2887, respectively. Equivalently, the mean and SD of the Z-score will be 0 and 1, respectively. These facts were used to statistically test the accuracy of the estimations. A p≥0.05 implies good model accuracy. In addition, possible relationships between Z-scores and age, height, weight, and sex were examined by ordinary linear regression models, with significant associations presented as Beta-coefficients. If the reference values are in perfect agreement with the observed values, no such relationship will exist.

The south-western Sweden sample

To evaluate the external validity of the OLIN reference values, they were also applied to spirometry data of a general population sample from another region in Sweden. In 2009–2012, clinical examinations were performed on a sample aged 17–78 years from the Swedish region of West Gothia (36). The examinations included dynamic spirometry also using a Jaeger Masterscope spirometer (JLAB version 5.03 software, CareFusion) and a structured interview with the same questions as in the interview for the northern Sweden sample. In total, 2,000 subjects were invited to participate in the clinical examinations, of which 1,172 (59%) participated. The study was approved by the Regional Ethical Review Board at the University of Gothenburg. From the participants, 358 healthy non-smoking subjects of European ancestry ≥22 years of age, 54% women, were identified using the same eligibility criteria for healthy non-smokers as in the northern Sweden reference sample. Percent of predicted, Z-scores (standardised residuals) and percentiles based on the OLIN reference values were calculated for each subject.

Comparison with the GLI reference values

The predicted sex- and age-specific FEV1, FVC and FEV1/FVC ratio (meanOLIN and LLNOLIN) was compared to predictions by the GLI reference values (meanGLI and LLNGLI). The comparisons are displayed in graphs, for a male of 180 cm and a female of 165 cm, which are approximately the sex-specific average heights in Sweden.

Results

Equations for the OLIN reference values for spirometry

As a result of the modelling technique, the SD, reference value (mean), and lower limit of normal (LLN, defined as the lower 5th percentile) for each of the spirometric indices are calculated by the following formulas: SD: A+B*age Mean: (B(J)*X(J))*SD LLN: Mean −1.645*SD where possible values for J ranges from 1–5, age is expressed in years, and the coefficients A, B, B1-5 and the variables X1-5 are found in Table 1. Calculation examples are illustrated in the Appendix.
Table 1

Equation coefficients for the OLIN reference values for spirometry

ABB1B2B3B4B5
FEV1Women0.3832−0.0013797−6.236984−0.001575−0.0021300.0008810.097457
Men0.5335−0.0013209−6.792881−0.016061−0.000654−0.0006310.092415
FVCWomen0.4835−0.0009121−7.504292−0.006537−0.001433−0.0004180.101606
Men0.6515−0.0009156−8.145885−0.024025−0.000089−0.0008880.100738
SVCWomen0.4890−0.0004222−6.585401−0.018584−0.000965−0.0007540.096274
Men0.6842−0.0013804−9.466451−0.013372−0.000253−0.0004100.105695
VCWomen0.4728−0.0004556−7.174368−0.016404−0.001117−0.0007750.101837
Men0.6852−0.0014865−9.237482−0.012298−0.000215−0.0005500.104602
FEV1/FVCWomen0.04140.000350121.774779−0.1219860.0002350.002045−0.014863
Men0.04740.000090420.349431−0.034677−0.0008160.000313−0.018407
FEV1/VCWomen0.03970.000410221.585726−0.1345900.0002160.002355−0.012948
Men0.05100.000070619.348156−0.033104−0.000538−0.000496−0.019745

The standard deviation (SD) is calculated by the following formula: A+B*age.

The reference value (i.e., the mean) is calculated by the following formula: (Σ B(J)*X(J))*SD.

The LLN (lower limit of normal) is calculated by the following formula: Mean-1.645*SD.

FEV1=Volume exhaled in the first second of a forced expiratory manoeuvre.

FVC=Forced expiratory vital capacity.

SVC=Slow expiratory vital capacity.

VC=The highest value of FVC and SVC.

X1=1.

X2=Age (in years).

X3=max(min(age-40, 20), 0)2+40*max(age-60, 0).

X4=max(min(age-60, 20), 0)2+40*max(age-80, 0).

X5=Height (in cm).

Equation coefficients for the OLIN reference values for spirometry The standard deviation (SD) is calculated by the following formula: A+B*age. The reference value (i.e., the mean) is calculated by the following formula: (Σ B(J)*X(J))*SD. The LLN (lower limit of normal) is calculated by the following formula: Mean-1.645*SD. FEV1=Volume exhaled in the first second of a forced expiratory manoeuvre. FVC=Forced expiratory vital capacity. SVC=Slow expiratory vital capacity. VC=The highest value of FVC and SVC. X1=1. X2=Age (in years). X3=max(min(age-40, 20), 0)2+40*max(age-60, 0). X4=max(min(age-60, 20), 0)2+40*max(age-80, 0). X5=Height (in cm). The mean ages for the 244 women and 257 men in the reference sample from northern Sweden were 49.2 (range 22–91) and 46.6 (range 22–86) years, respectively. The mean height was 163.3 cm (range 139.0–181.0) for women and 178.9 cm (range 162.5–198.0) for men, and the mean weight was 68.2 kg (range 45.0–118.0) for women and 84.8 kg (range 56.0–148.0) for men. These are the ranges of age, height, and weight in which the equations for the OLIN reference values are valid.

Model accuracy check based on the northern Sweden reference sample

Mean observed and predicted values, observed values as percent of predicted values, Z-scores and percentiles for the reference sample (n=501) are shown in Table 2, stratified by sex and three age groups. The mean observed values and predicted values were close to identical, which yielded mean percent of predicted close to 100%. Correspondingly, the mean Z-scores were approximately 0 with SDs close to 1, and mean percentile points are approximately 0.5 with SDs close to 0.288. Statistical testing revealed that the models for all spirometric indices were concordant with the observed values. These results were equivalent across all age groups and for both sexes. No significant associations between the Z-scores and sex, age, height or weight were found.
Table 2

Evaluation of the OLIN reference values on the northern Sweden reference sample

Observed valuesPredicted valuesPredicted LLN% of predictedZ-scorePercentile point






Age groupMeanSDMeanSDMeanSDMeanSDMeanSDMeanSD P
Among women
22–39 years n=106FEV13.3180.4113.3160.2092,7630.205100.010.40.0061.0180.49190.2800.773
FVC4.1410.5394.1220.2803.3780.278100.410.90.0431.0030.50600.2620.831
SVC4.1570.5544.1460.2803.3650.279100.211.10.0240.9830.50470.2640.867
VC4.1950.5454.1810.2843.4280.283100.310.90.0321.0010.50530.2660.850
FEV1/FVC0.8040.0540.8090.0060.7200.00899.56.6−0.0691.0030.48090.2830.496
FEV1/VC0.7930.0550.7960.0060.7080.00899.66.8−0.0511.0080.48910.2800.698
40–59 years n=74FEV12.9730.4012.9750.2822.4560.271100.010.6−0.0080.9900.50410.2970.903
FVC3.7810.5293.8080.3383.0860.33299.511.9−0.0621.0330.47760.2910.504
SVC3.8150.5763.8340.3343.0640.33199.713.2−0.0411.0840.49290.2890.832
VC3.8520.5403.8740.3383.1330.33599.612.0−0.0481.0320.48290.2870.610
FEV1/FVC0.7890.0620.7820.0150.6860.018100.97.50.1191.0060.54220.2900.209
FEV1/VC0.7740.0610.7690.0170.6700.021100.77.70.0950.9870.53200.2920.340
60–91 years n=64FEV12.0360.4712.0340.3661.5740.348100.014.20.0061.0060.49820.2940.960
FVC2.7340.6672.7370.5192.0540.50799.915.0−0.0070.9780.48320.2890.642
SVC2.8170.6992.8140.5282.0610.522100.015.20.0070.9470.48810.2810.744
VC2.8300.7012.8310.5382.1100.53299.915.0−0.0030.9830.48280.2880.636
FEV1/FVC0.7500.0690.7490.0090.6380.008100.09.10.0041.0020.50780.2850.829
FEV1/VC0.7260.0720.7260.0090.6110.00999.99.9−0.0071.0190.50300.2950.934
All ages n=244FEV12.8770.6732.8770.5932.3580.555100.011.50.0021.0020.49720.2870.880
FVC3.6630.8103.6630.6802.9420.656100.012.3−0.0021.0030.49140.2770.642
SVC3.7060.8113.7060.6602.9350.649100.012.90.0001.0020.49680.2750.863
VC3.7370.8083.7370.6702.9960.658100.012.3−0.0011.0020.49270.2770.693
FEV1/FVC0.7850.0640.7850.0260.6880.035100.17.60.0071.0030.50650.2860.725
FEV1/VC0.7700.0670.7700.0300.6710.042100.07.90.0051.0020.50580.2870.754
Among men
22–39 years n=118FEV14.5960.5804.5790.3163.7750.313100.410.30.0361.0560.50650.2800.807
FVC5.7600.7605.7400.4324.7190.430100.310.60.0320.9850.50140.2770.958
SVC5.8760.5545.8560.4614.8070.459100.310.90.0321.0040.50380.2800.886
VC5.8960.7905.8750.4554.8310.453100.410.70.0341.0000.49670.2800.901
FEV1/FVC0.8000.0520.8000.0060.7170.007100.16.50.0111.0270.50430.2880.872
FEV1/VC0.7820.0560.7830.0080.6950.008100.07.2−0.0071.0560.50010.2900.997
40–59 years n=84FEV14.1770.5804.1930.3463.4190.33899.711.8−0.0331.0440.49310.3020.827
FVC5.2830.7415.3010.4484.3010.44399.812.2−0.0281.0420.49720.3040.929
SVC5.4130.7445.4290.4714.4120.46499.811.7−0.0251.0130.49740.3010.934
VC5.4280.7395.4480.4644.4380.45799.711.7−0.0311.0220.49670.3030.917
FEV1/FVC0.7930.0500.7920.0060.7070.009100.06.10.0090.9370.50750.2800.812
FEV1/VC0.7710.0500.7710.0100.6820.010100.06.10.0021.0860.50560.2760.859
60–86 years n=55FEV13.2850.6573.2970.5032.5760.48899.713.4−0.0251.0200.48990.2930.795
FVC4.3620.8384.3820.6253.4190.61599.613.6−0.0340.9910.48390.2850.679
SVC4.5170.8444.5350.6053.5730.59099.613.3−0.0310.9970.48360.2820.674
VC4.5360.8374.5530.6053.6030.58999.613.0−0.0300.9920.48320.2800.666
FEV1/FVC0.7540.0580.7530.0140.6650.015100.27.60.0221.0650.51670.2840.668
FEV1/VC0.7250.0640.7250.0210.6330.022100.08.50.0021.0860.51260.2970.746
All ages n=257FEV14.1790.7774.1790.6163.4020.586100.011.50.0001.0020.49860.2890.938
FVC5.3050.9365.3060.7094.3040.690100.011.8−0.0011.0020.49630.2870.837
SVC5.4340.9435.4340.7084.4140.680100.011.70.0001.0020.49740.2860.885
VC5.4520.9395.4530.7054.4390.675100.011.6−0.0011.0020.49700.2860.868
FEV1/FVC0.7880.0560.7870.0200.7020.022100.16.60.0131.0030.50800.2840.657
FEV1/VC0.7660.0600.7660.0250.6770.027100.07.2−0.0021.0020.50460.2860.798

A P<0.05 indicates a non-perfect model fit.

Evaluation of the OLIN reference values on the northern Sweden reference sample A P<0.05 indicates a non-perfect model fit.

Applying the OLIN reference values to the south-western Sweden sample

The OLIN reference values were applied to the south-western Sweden sample, and percent of predicted, Z-scores and percentiles were calculated for each subject. The mean percent of predicted was close to 100% and mean absolute values of the Z-scores are approximately≤0.4, corresponding to approximately≤3% of predicted, for all spirometric indices in both age groups and for both sexes in the south-western Sweden sample (n=358). However, statistical testing revealed that the model fit was not perfect for some of the spirometric indices, especially among women (Table 3). Also, small but statistically significant associations between the Z-scores and sex were found for FEV1, SVC, and VC such that women on average had higher Z-scores than men when corrected for age and height (B-coefficients between 0.331 and 0.453). When also corrected for weight, the association between the Z-scores for FVC and FEV1/FVC reached statistical significance for female sex (B-coefficients of 0.330 and 0.177, respectively). No other statistically significant associations between the Z-scores and age, height, or weight were found when weight was included, except for the Z-score for FVC where height measured in cm yielded a B-coefficient of 0.018 with p-value 0.049.
Table 3

Evaluation of the OLIN reference values on the south-western Sweden sample

WomenMen


% of predictedZ-scorePercentile point% of predictedZ-scorePercentile point






Age groupMeanSDMeanSDMeanSD P MeanSDMeanSDMeanSD P
22–39 yearsFEV1101.710.50.1761.0320.5380.2790.27898.410.9−0.1511.0380.4750.2940.466
n=68 womenFVC99.710.6−0.0170.9640.4820.2830.60798.610.7−0.1351.0110.4690.3010.366
n=71 menSVC99.010.8−0.0760.9520.4640.2800.30497.110.5−0.2760.9790.4250.2820.029
VC99.210.5−0.0590.9650.4670.2810.34697.310.5−0.2540.9910.4350.2870.058
FEV1/FVC102.17.30.3391.1560.5840.3110.01699.87.0−0.0270.9310.4980.3020.953
FEV1/VC102.67.50.4131.1630.6060.3080.002100.97.20.1321.0650.5450.2850.189
40–77 yearsFEV199.611.6−0.0291.0390.4890.3040.67997.511.7−0.2051.0240.4540.2810.109
n=118 womenFVC96.211.1−0.2890.9260.4140.2730.00198.612.1−0.1061.0540.4680.3050.265
n=101 menSVC96.411.2−0.2560.8930.4180.2650.00297.812.1−0.1741.0640.4500.3050.082
VC96.210.9−0.2870.9110.4110.2660.00198.211.8−0.1451.0620.4350.3040.024
FEV1/FVC103.37.80.4050.9630.6160.266<0.00199.06.3−0.1550.9310.4580.2750.144
FEV1/VC103.38.30.3750.9780.6160.286<0.00199.47.0-0.0880.9540.4800.2790.486
All agesFEV1100.411.20.0461.0380.5070.2950.74197.911.4−0.1831.0270.4630.2860.093
n=186 womenFVC97.511.0−0.1890.9470.4390.2780.00498.611.5−0.1181.0340.4690.3020.159
n=172 menSVC97.311.1−0.1760.9200.4350.2710.00297.511.4−0.2171.0270.4390.2950.006
VC97.310.8−0.2040.9350.4320.2720.00197.811.3−0.1901.0320.4480.2970.018
FEV1/FVC102.97.60.3811.0350.6040.283<0.00199.36.6−0.1021.0130.4750.2860.256
FEV1/VC103.08.00.3891.0460.6120.293<0.001100.07.10.0031.0040.5060.2830.785

A P<0.05 indicates a non-perfect model fit.

Evaluation of the OLIN reference values on the south-western Sweden sample A P<0.05 indicates a non-perfect model fit.

Comparison with GLI

The predicted meanGLI for FEV1 in the northern Sweden reference sample was on average 67 ml lower (p<0.001) than the predicted meanOLIN for women and 103 ml lower (p<0.001) than the predicted meanOLIN for men. For FVC, the predicted meanGLI was on average 203 ml lower for women (p<0.001) and 190 ml lower for men (p<0.001). The average predicted meanGLI for the FEV1/FVC ratio was 0.028 units higher (p<0.001) for women and 0.011 units higher for men (p<0.001). To make further comparisons to the GLI reference values, the predicted reference values of FEV1, FVC and the FEV1/FVC ratio (mean and LLN) for a woman and man of average height are plotted by age in Fig. 2a–f. The comparisons showed that for a man of average height, meanGLI for both FEV1 and, in particular, for FVC, were lower than meanOLIN across the ages 22–86 years. For a woman of average height, meanOLIN and meanGLI for FEV1 were similar, but meanGLI FVC is constantly lower than meanOLIN FVC. Consequently, the meanGLI FEV1/FVC ratio was also consistently lower than the meanOLIN for the woman. For a woman of average height, the LLNGLI and LLNOLIN for the FEV1/FVC ratio was well in concordance throughout the age span, but less so for FEV1 and FVC where LLNGLI was consistently lower than LLNOLIN. The pattern was somewhat different for the average height man, where the gap between LLNGLI and LLNOLIN increased with increasing age for all three spirometric indices. LLNGLI for the FEV1/FVC ratio reached below 0.7 at the age between 46 and 47 years for a woman of average height and at the age 39–40 years for a man of average height. The corresponding ages when LLNOLIN reached below 0.7 for the FEV1/FVC ratio are 43–44 years for the woman and 53–54 years for the man. Both the LLNGLI and LLNOLIN for FEV1/FVC reached below 0.7 in earlier stages in life for taller subjects compared to for shorter subjects of both sexes.
Fig. 2

(a–f) Sex- and age-dependent decline in the OLIN reference values (mean and LLN) in comparison with GLI. The predicted mean and LLN for the OLIN and the GLI reference values are plotted against age, for FEV1, FVC and the FEV1/FVC ratio, respectively. Figures (a), (b) and (c) display predicted values for a 165 cm tall woman, while (d), (e) and (f) display predicted values for a 180 cm tall man.

(a–f) Sex- and age-dependent decline in the OLIN reference values (mean and LLN) in comparison with GLI. The predicted mean and LLN for the OLIN and the GLI reference values are plotted against age, for FEV1, FVC and the FEV1/FVC ratio, respectively. Figures (a), (b) and (c) display predicted values for a 165 cm tall woman, while (d), (e) and (f) display predicted values for a 180 cm tall man.

Discussion

The modelling approach in this study produced unbiased estimates of mean observed values in the reference sample from northern Sweden. The approach to model lung function by linear regression is a powerful technique, which we successfully extended to let the SD depend on age. In general, the GLI reference values for FEV1 and FVC were lower than the corresponding values in our sample, but higher for the FEV1/FVC ratio. In addition, the SD for the GLI reference values was larger for all spirometric indices, which can impact the LLN. Furthermore, the results indicate a high external validity for Swedish conditions, when evaluated on the sample from south-western Sweden. Historically, multivariable linear regression has commonly been used to model spirometric outcomes since it is robust and straight-forward. However, linear regression assumes that the outcome variable is normally distributed; an assumption not always true for all spirometric indices (3, 10). In addition, traditional multivariable linear regression modelling does not incorporate the dependence that exists between the dispersion around the spirometric outcome and age (10, 25), that is, one of the independent or explanatory variables. In this study however, we found all spirometric outcomes to be reasonably normally distributed. A new approach to model spirometric outcomes by linear regression is presented, where the sex-specific spirometric outcomes are predicted by age and height, and where the SD also is allowed to linearly depend on age. Because of the strengths of linear regression modelling mentioned above, this approach presents a useful technique which can be used to model lung function in an efficient way. It is essential that reference values are evaluated and updated frequently in order to confirm that the classifications of normal and abnormal reflects the realities of the contemporary general population (22, 24, 25). It has recently been shown that the GLI reference values may not be appropriate for all countries (16–20). The comparison between these new Swedish reference values, that is, the OLIN reference values, and the GLI reference values show that, on average, both the predicted mean values and LLN for FEV1, FVC and FEV1/FVC for a woman and man of average height differ across the entire life span with differences generally more pronounced in older ages. Despite recent debate of its appropriateness (37), classification of airway and lung disease severity often relies on FEV1 and FVC expressed as percent of the predicted value (38). Also, since the LLN for the FEV1/FVC ratio is used as a key element for the diagnosis of airway obstruction, the use of GLI may lead to invalid diagnosis of airway obstruction along with erroneous classification of airway and lung disease severity in the Swedish population (17). A prominent advantage of the GLI reference values is that they cover an extensive age span and different ethnicities, and thus provide estimates without junction points. The GLI reference values for Caucasians are based on collated data from>57,000 subjects, and estimations based on such an extensive amount of data are likely to be valid. Undoubtedly, the GLI is an extremely valuable contribution to the field of lung function reference values, and provide the opportunity to compare a subject or a population to the world-wide average within each ethnicity which is of substantial value for, for example, international multi-centre studies. Quanjer et al. (39) has previously shown that the GLI SDs are expected to be larger compared to SDs derived from smaller populations due to the large number of data subsets included in the estimation of GLI, an expectation which is confirmed in our sample (17). Quanjer et al. argue that although the LLN according to GLI will identify a somewhat larger proportion of subjects as below LLN in smaller populations compared to in larger populations, this will not lead to any bias since the smaller populations merely are subsets of the population at large. However, we argue that since there are considerable differences in, for example, environmental pollution, occupational exposures and socio-economic factors which can affect lung function between regions (21), bias can indeed be introduced and observed differences should not be neglected. In addition, although the GLI reference values currently are recommended by many respiratory societies, the consensus is still that, when available, appropriate and applicable local population-specific reference values may be preferred (22, 23, 25). This consensus is confirmed in our study. An advantage of our study is that, along with FEV1 and FVC, reference values are provided also for SVC and for the highest value of the forced and slow VC, that is, the VC. Although the FVC is a recognised proxy for the VC, additional information of the lung function can be obtained by measuring the SVC, especially in subjects where FVC is reduced by air-trapping due to small-airways obstruction, for example, at early stages of COPD. For example, it is common practice that the FEV1/VC ratio is relied on when diagnosing obstruction and the GOLD criteria for the diagnosis of COPD recognise this alternative to the FEV1/FVC ratio (38), but hitherto few recently published studies provide reference values (and LLN) also for SVC and VC. A weakness of our study is that the age range does not cover children or adults younger than 22 years, that sitting height was not recorded although it has been argued to be a better predictor than standing height (20, 26) and that the geographical coverage was limited to northern Sweden. The small but still observable differences in lung function between the samples from northern and south-western Sweden could possibly be due to minor technical or procedural differences, which are not uncommon (39), while substantial biological differences are more unlikely. Two spirometers, instead of only one, were used for the northern Sweden sample. However, they were of identical brand and model which limits the possible bias. The spirometers were calibrated on a daily basis, but the syringes were not sent for yearly calibration according to the ERS/ATS recommendations and there is a lack of calibration traceability. Further, future studies would most likely benefit from European Spirometry Driving Licenses for the staff and deep insight in previous study protocols such as the NHANES (40, 41). However, all measurements in this study were performed by the same three well-trained research nurses with an extensive experience. Also, seasonal variation effects on lung function are avoided due to the random sampling over several years, regardless of season. The random sample size of 501 subjects is greater than the sample sizes in commonly used Swedish reference values (1, 4, 5) and suffices to produce valid estimates, results in line with previous studies (39). It is possible that our eligibility criteria are too strict and consequently exclude too many subjects, particularly among the elderly. However, obstructive lung diseases, smoking history, breathlessness, cough and wheeze have been shown to be feasible exclusion criteria to define healthy non-smokers in reference populations for spirometry (25, 42). Since the same structured interview questions were used in northern and south-western Sweden, these criteria could be applied identically for both samples. The reference sample from northern Sweden constitutes a representative sample of the general healthy non-smoking population of the area. Thus, bias introduced by including smokers (1, 4, 5) or by using selected samples such as workers from specific industries (13) or respiratory healthy patients from certain hospitals is avoided. The evaluation of the reference values in the south-western Sweden sample yielded mean Z-scores close to 0 and Z-score SDs close to 1, with corresponding mean percent of predicted close to 100%, for all six different spirometric parameters. Although statistical differences were observed for some of the spirometric parameters, the evaluations reveal a high external validity. To summarise, the evaluation of the OLIN reference values based on the reference sample of healthy non-smokers from northern Sweden show that the models are valid. Further, the evaluation based on the healthy non-smokers from south-western Sweden indicates a high external validity of the model. The comparison with GLI brought further evidence to the consensus that, when available, appropriate local population-specific reference values may be preferred.
  38 in total

1.  Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trøndelag Study.

Authors:  A Langhammer; R Johnsen; A Gulsvik; T L Holmen; L Bjermer
Journal:  Eur Respir J       Date:  2001-11       Impact factor: 16.671

2.  The recent multi-ethnic global lung initiative 2012 (GLI2012) reference values don't reflect contemporary adult's North African spirometry.

Authors:  Helmi Ben Saad; Mohamed Nour El Attar; Khaoula Hadj Mabrouk; Ahmed Ben Abdelaziz; Ahmed Abdelghani; Mohamed Bousarssar; Khélifa Limam; Chiraz Maatoug; Hmida Bouslah; Ameur Charrada; Sonia Rouatbi
Journal:  Respir Med       Date:  2013-10-30       Impact factor: 3.415

3.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

4.  Implications of adopting the Global Lungs Initiative 2012 all-age reference equations for spirometry.

Authors:  Philip H Quanjer; Danny J Brazzale; Piotr W Boros; Jeffrey J Pretto
Journal:  Eur Respir J       Date:  2013-03-21       Impact factor: 16.671

5.  Reference values for lung function tests in females. Regression equations with smoking variables.

Authors:  H Hedenström; P Malmberg; K Agarwal
Journal:  Bull Eur Physiopathol Respir       Date:  1985 Nov-Dec

6.  Feasible and simple exclusion criteria for pulmonary reference populations.

Authors:  Ane Johannessen; Ernst R Omenaas; Geir Egil Eide; Per S Bakke; Amund Gulsvik
Journal:  Thorax       Date:  2007-03-27       Impact factor: 9.139

7.  Global differences in lung function by region (PURE): an international, community-based prospective study.

Authors:  MyLinh Duong; Shofiqul Islam; Sumathy Rangarajan; Koon Teo; Paul M O'Byrne; Holger J Schünemann; Ehimario Igumbor; Jephat Chifamba; Lisheng Liu; Wei Li; Tengku Ismail; Kiruba Shankar; Muhammad Shahid; Krishnapillai Vijayakumar; Rita Yusuf; Katarzyna Zatonska; Aytekin Oguz; Annika Rosengren; Hossain Heidari; Wael Almahmeed; Rafael Diaz; Gustavo Oliveira; Patricio Lopez-Jaramillo; Pamela Seron; Kieran Killian; Salim Yusuf
Journal:  Lancet Respir Med       Date:  2013-09-10       Impact factor: 30.700

8.  Secular changes in relative leg length confound height-based spirometric reference values.

Authors:  Philip H Quanjer; Masaru Kubota; Hirosuke Kobayashi; Hisamitsu Omori; Koichiro Tatsumi; Minoru Kanazawa; Sanja Stanojevic; Janet Stocks; Tim J Cole
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

9.  Evaluation of the global lung function initiative 2012 reference values for spirometry in a Swedish population sample.

Authors:  Helena Backman; Anne Lindberg; Anssi Sovijärvi; Kjell Larsson; Bo Lundbäck; Eva Rönmark
Journal:  BMC Pulm Med       Date:  2015-03-25       Impact factor: 3.317

10.  Increase in sensitization to common airborne allergens among adults - two population-based studies 15 years apart.

Authors:  Katja Warm; Anne Lindberg; Bo Lundbäck; Eva Rönmark
Journal:  Allergy Asthma Clin Immunol       Date:  2013-06-11       Impact factor: 3.406

View more
  12 in total

1.  Hand grip strength is associated with forced expiratory volume in 1 second among subjects with COPD: report from a population-based cohort study.

Authors:  Viktor Johansson Strandkvist; Helena Backman; Jenny Röding; Caroline Stridsman; Anne Lindberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-10-07

2.  Ischemic heart disease among subjects with and without chronic obstructive pulmonary disease--ECG-findings in a population-based cohort study.

Authors:  Ulf Nilsson; Bengt Johansson; Berne Eriksson; Anders Blomberg; Bo Lundbäck; Anne Lindberg
Journal:  BMC Pulm Med       Date:  2015-12-04       Impact factor: 3.317

3.  A population-based cohort of adults with asthma: mortality and participation in a long-term follow-up.

Authors:  Helena Backman; Linnea Hedman; Caroline Stridsman; Sven-Arne Jansson; Anne Lindberg; Bo Lundbäck; Eva Rönmark
Journal:  Eur Clin Respir J       Date:  2017-06-16

4.  Pre- and post-bronchodilator airway obstruction are associated with similar clinical characteristics but different prognosis - report from a population-based study.

Authors:  Sami Sawalha; Linnea Hedman; Eva Rönmark; Bo Lundbäck; Anne Lindberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-04-24

5.  Measures of bronchodilator response of FEV1, FVC and SVC in a Swedish general population sample aged 50-64 years, the SCAPIS Pilot Study.

Authors:  K Torén; B Bake; A-C Olin; G Engström; A Blomberg; J Vikgren; J Hedner; J Brandberg; H L Persson; C M Sköld; A Rosengren; G Bergström; C Janson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-03-22

6.  Cardiac biomarkers of prognostic importance in chronic obstructive pulmonary disease.

Authors:  Ulf Nilsson; Nicholas L Mills; David A McAllister; Helena Backman; Caroline Stridsman; Linnea Hedman; Eva Rönmark; Takeshi Fujisawa; Anders Blomberg; Anne Lindberg
Journal:  Respir Res       Date:  2020-06-26

7.  Among respiratory symptoms, wheeze associates most strongly with impaired lung function in adults with asthma: a long-term prospective cohort study.

Authors:  Nicolás Bermúdez Barón; Anne Lindberg; Caroline Stridsman; Martin Andersson; Linnea Hedman; Sigrid Anna Vikjord; Hannu Kankaanranta; Bo Lundbäck; Eva Rönmark; Helena Backman
Journal:  BMJ Open Respir Res       Date:  2021-07

8.  Ischemic ECG abnormalities are associated with an increased risk for death among subjects with COPD, also among those without known heart disease.

Authors:  Ulf Nilsson; Anders Blomberg; Bengt Johansson; Helena Backman; Berne Eriksson; Anne Lindberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-22

9.  The COPD Assessment Test (CAT) can screen for fatigue among patients with COPD.

Authors:  Caroline Stridsman; My Svensson; Viktor Johansson Strandkvist; Linnea Hedman; Helena Backman; Anne Lindberg
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

10.  FEV1 decline in relation to blood eosinophils and neutrophils in a population-based asthma cohort.

Authors:  Helena Backman; Anne Lindberg; Linnea Hedman; Caroline Stridsman; Sven-Arne Jansson; Thomas Sandström; Bo Lundbäck; Eva Rönmark
Journal:  World Allergy Organ J       Date:  2020-03-17       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.